Cabaletta Bio (CABA) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Cabaletta Bio (CABA) over the past year, gaining 22.4% versus a loss of 16.8%. Over five years, IKT leads with a -83.0% price change compared with -84.3% for CABA. Cabaletta Bio is the larger company by market cap ($327.2 million vs $274.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | IKT |
|---|---|---|
| Share price | $1.93 | $1.97 |
| Market cap | $327.22M | $274.89M |
| 1-day change | -1.03% | +3.14% |
| YTD return | -11.87% | -3.90% |
| 1-year return | -16.81% | +22.36% |
| 5-year return | -84.26% | -82.99% |
| EPS (TTM) | $-1.51 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $2.61 |
| 52-week low | $1.83 | $1.33 |
| Distance from 52-week high | -54.37% | -24.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +586.53% | +204.57% |
| Average volume | 4.61M | 650.50K |
| Shares outstanding | 169.55M | 139.54M |
| Employees | 154 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed CABA by 39.2 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
CABA vs IKT FAQ
Which is bigger, Cabaletta Bio or Inhibikase Therapeutics?
Cabaletta Bio (CABA) is larger, with a market capitalization of $327.22M compared with $274.89M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, CABA or IKT?
IKT returned +22.36% over the past 12 months, compared with -16.81% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Inhibikase Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.